BMGL
BEARISH
$0.8
Live
Basel Medical Group Ltd · NASDAQ
$0.49
52W Range
$9.4
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$15.03M
P/E
N/A
ROE
-194.6%
Profit margin
-99.8%
Debt/Equity
1.04
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a positive revenue growth of 32.20% YoY and a gross margin of 26.29%, the company suffers from catastrophic profitability metrics including a -99.84% profit margin and -194.56% ROE, which undermine sustainable growth. Valuation multiples like Price/Book of 3.96 appear high given the lack of earnings and cash flow visibility, while the stock has lost over 80% of its value in the past year. The absence of Altman Z-Score and intrinsic value estimates further reflects data insufficiency and elevated distress risk.
Key Strengths
Revenue growth of 32.20% YoY indicates some top-line momentum
Gross margin of 26.29% suggests basic operational viability in core services
Current ratio of 1.23 and quick ratio of 1.15 indicate short-term liquidity adequacy
Debt/Equity of 1.04 is below sector average of 2.55, implying relatively moderate leverage
Recent 1-month price increase of +23.8% may signal speculative or technical rebound
Key Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and high risk of deterioration
Profit margin of -99.84% and ROE of -194.56% indicate severe unprofitability and capital destruction
No Altman Z-Score available, but negative earnings and ROE imply potential distress risk (Z < 1.8 likely)
Lack of meaningful cash flow, debt, and share count data creates information opacity
Stock down over 80% in 1Y, 3Y, and 5Y periods, reflecting prolonged investor erosion
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
20
55
15
10
0
AI Verdict
High-risk speculative position with fundamental deterioration outweighing growth signals
Key drivers: Piotroski F-Score of 2, Negative profitability across all margins, Absence of Altman Z-Score and cash flow data, Strong revenue growth not translating to earnings
Confidence
80%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 3.96 is below sector average P/E of 215, though not directly comparable
Watchpoints
- P/E, Forward P/E, PEG all N/A due to lack of earnings
- No Graham Number or intrinsic value estimate available
- Price/Sales of 1.24 lacks context without profit conversion
Future
55/100
Ref Growth rates
Positives
- Revenue growth of 32.20% YoY is strong and above some peers like ACON
Watchpoints
- Earnings growth data unavailable; current losses suggest negative trajectory
- No visibility on future cash flows or guidance
Past
15/100
Ref Historical trends
Positives
- 1-month return of +23.8% shows short-term technical resilience
Watchpoints
- 5Y, 3Y, and 1Y returns all at -82.0%, indicating chronic underperformance
- 52-week high of $9.40 vs current $0.80 implies 91.5% decline from recent peak
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios above 1.0 suggest short-term solvency
Watchpoints
- Piotroski F-Score of 2/9 indicates poor financial health
- ROE of -194.56% and negative operating leverage
- No Altman Z-Score reported, but financials suggest likely distress zone
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100 and no yield or payout history
- No indication of dividend policy or capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.8
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BMGL and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd
Primary
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
|
ICU
SeaStar Medical Holding Corporation
Peer
|
-99.8% | -99.3% | -70.8% | -35.1% | +33.9% | -13.9% |
|
HIND
Vyome Holdings, Inc.
Peer
|
-100.0% | -100.0% | -96.1% | -56.8% | -15.1% | +2.8% |
|
HKPD
Cellyan Biotechnology Co., Ltd
Peer
|
-77.9% | -77.9% | -40.8% | -47.7% | -1.0% | +9.3% |
BMG
Basel Medical Group Ltd
Primary
5Y
-82.0%
3Y
-82.0%
1Y
-82.0%
6M
-64.4%
1M
+23.8%
1W
-3.5%
CYC
Cyclerion Therapeutics, Inc.
Peer
5Y
-93.9%
3Y
-46.5%
1Y
+40.9%
6M
+36.5%
1M
+133.6%
1W
+124.5%
ICU
SeaStar Medical Holding Corporation
Peer
5Y
-99.8%
3Y
-99.3%
1Y
-70.8%
6M
-35.1%
1M
+33.9%
1W
-13.9%
HIN
Vyome Holdings, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.1%
6M
-56.8%
1M
-15.1%
1W
+2.8%
HKP
Cellyan Biotechnology Co., Ltd
Peer
5Y
-77.9%
3Y
-77.9%
1Y
-40.8%
6M
-47.7%
1M
-1.0%
1W
+9.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
3.96
P/S Ratio
1.24
EV/Revenue
0.85
EV/EBITDA
-9.1
Market Cap
$15.03M
Profitability
Profit margins and return metrics
Profit Margin
-99.84%
Operating Margin
-9.47%
Gross Margin
26.29%
ROE
-194.56%
ROA
-4.67%
Growth
Revenue and earnings growth rates
Revenue Growth
+32.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.04
Moderate
Current Ratio
1.23
Good
Quick Ratio
1.15
Good
Cash/Share
$0.52
Healthcare Sector Comparison
Comparing BMGL against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-194.56%
This Stock
vs
-88.14%
Sector Avg
+120.7%
(Excellent)
Profit Margin
-99.84%
This Stock
vs
-16.28%
Sector Avg
+513.3%
(Superior)
Debt to Equity
1.04
This Stock
vs
2.66
Sector Avg
-60.9%
(Less Debt)
Revenue Growth
32.2%
This Stock
vs
124.04%
Sector Avg
-74.0%
(Slower)
Current Ratio
1.23
This Stock
vs
4.47
Sector Avg
-72.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
|
ICU
SeaStar Medical Holding Corporation
|
BEARISH | $14.82M | - | -295.2% | -% | $3.71 | Compare |
|
HIND
Vyome Holdings, Inc.
|
BEARISH | $15.37M | - | -% | -% | $2.19 | Compare |
|
HKPD
Cellyan Biotechnology Co., Ltd
|
BEARISH | $14.62M | - | -13.4% | -4.3% | $0.62 | Compare |
BMGL
Basel Medical Group Ltd
BEARISH
Mkt Cap
$15M
P/E
-
ROE
-194.6%
Price
$0.8
Past News Coverage
Recent headlines mentioning BMGL from our newsroom.
Newest → oldest
No matching news yet.